Company
Amporin Pharmaceuticals
Repairing Membranes to Rescue Mitochondria in Degenerative Diseases
Also known as Amporin, Amporin Pharmaceuticals AG
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Basel, Switzerland
- Founded
- 2024
- Customers
- licensing and co-development partners
- Legal name
- Amporin Pharmaceuticals AG
Claim, correct or request removal
Record updated 18 September 2026
About
Amporin is developing the first class of oral small-molecule drugs designed to target toxic membrane pores formed by misfolded protein oligomers across multiple degenerative diseases, including Alzheimer's, Parkinson's, Type 2 diabetes, and numerous rare disorders.
Funding snapshot
- Latest round
- Seed extension2024-12-18
Funding rounds
- Seed extension
- 2024-12-18
- Seed
- 2024-07-25
Loading relationship preview